1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Globoid Cell Leukodystrophy (Krabbe Disease) - Drugs In Development, 2022, provides an overview of the Globoid Cell Leukodystrophy (Krabbe Disease) (Central Nervous System) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Krabbe disease also called globoid cell leukodystrophy is a degenerative disorder caused by the deficiency of an enzyme called galactosylceramidase. This enzyme deficiency impairs the growth and maintenance of myelin. Symptoms include seizures, Muscle spasms, Loss of head control, vomiting, fevers, irritability and excessive crying. Risk factors include family history. Treatment focuses on managing symptoms (anticonvulsant, muscle relaxer) and providing supportive care.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Globoid Cell Leukodystrophy (Krabbe Disease) - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Globoid Cell Leukodystrophy (Krabbe Disease) (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Globoid Cell Leukodystrophy (Krabbe Disease) (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Globoid Cell Leukodystrophy (Krabbe Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Preclinical and Discovery stages are 1, 6 and 4 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 1 molecules, respectively.
Globoid Cell Leukodystrophy (Krabbe Disease) (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Globoid Cell Leukodystrophy (Krabbe Disease) (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Globoid Cell Leukodystrophy (Krabbe Disease) (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Globoid Cell Leukodystrophy (Krabbe Disease) (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Globoid Cell Leukodystrophy (Krabbe Disease) (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Globoid Cell Leukodystrophy (Krabbe Disease) (Central Nervous System)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Globoid Cell Leukodystrophy (Krabbe Disease) (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Globoid Cell Leukodystrophy (Krabbe Disease) (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Globoid Cell Leukodystrophy (Krabbe Disease) - Overview
- Globoid Cell Leukodystrophy (Krabbe Disease) - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Globoid Cell Leukodystrophy (Krabbe Disease) - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Globoid Cell Leukodystrophy (Krabbe Disease) - Companies Involved in Therapeutics Development
- Apteeus SAS
- Bial - Portela & Ca SA
- BioXcel Corp
- Forge Biologics Inc
- Gain Therapeutics Inc
- M6P Therapeutics
- Neurogene Inc
- Polaryx Therapeutics Inc
- Vascumab LLC
- Globoid Cell Leukodystrophy (Krabbe Disease) - Drug Profiles
- Drug for Krabbe Disease - Drug Profile
- Product Description
- Mechanism Of Action
- DUOC-01 - Drug Profile
- Product Description
- Mechanism Of Action
- FBX-101 - Drug Profile
- Product Description
- Mechanism Of Action
- gemfibrozil - Drug Profile
- Product Description
- Mechanism Of Action
- Gene Therapy for Globoid Cell Leukodystrophy - Drug Profile
- Product Description
- Mechanism Of Action
- Gene Therapy to Activate GALC for Globoid Cell Leukodystrophy (Krabbe Disease) - Drug Profile
- Product Description
- Mechanism Of Action
- Krabbe Disease - Drug Profile
- Product Description
- Mechanism Of Action
- Krabbe Disease - Drug Profile
- Product Description
- Mechanism Of Action
- M-031 - Drug Profile
- Product Description
- Mechanism Of Action
- M-033 - Drug Profile
- Product Description
- Mechanism Of Action
- PLX-300 - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecule to Inhibit Acid Ceramidase for Gaucher's and Krabbe's Diseases - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecules to Activate GALC for Krabbe Disease - Drug Profile
- Product Description
- Mechanism Of Action
- Globoid Cell Leukodystrophy (Krabbe Disease) - Dormant Projects
- Globoid Cell Leukodystrophy (Krabbe Disease) - Discontinued Products
- Globoid Cell Leukodystrophy (Krabbe Disease) - Product Development Milestones
- Featured News & Press Releases
- Oct 12, 2022: Forge Biologics announces updated positive clinical data in RESKUE, a novel phase 1/2 gene therapy trial for patients with Krabbe Disease
- Sep 27, 2022: Forge Biologics fuels gene therapy manufacturing engine with launch of plasmid DNA manufacturing services to support AAV clients
- Aug 31, 2022: Forge Biologics reports positive clinical data on brain development and motor function from the RESKUE novel phase 1/2 gene therapy trial in patients with krabbe disease at the SSIEM Annual Symposium
- Sep 20, 2021: Forge Biologics announces regulatory updates from FDA and EMA, accelerating manufacturing and clinical trial momentum
- Feb 16, 2021: Forge Biologics Receives FDA Fast Track, Orphan Drug, and Rare Pediatric Disease Designations for FBX-101 Gene Therapy for Patients with Krabbe Disease
- Feb 10, 2021: Polaryx Therapeutics receives both Rare Pediatric Disease and Orphan Drug Designations for the treatment of Krabbe Disease with PLX-300
- Jan 04, 2021: Forge Biologics announces FDA clearance of Investigational New Drug application for phase 1/2 clinical trial (RESKUE) of FBX-101 gene therapy for patients with Krabbe disease
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- Number of Products under Development for Globoid Cell Leukodystrophy (Krabbe Disease), 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Globoid Cell Leukodystrophy (Krabbe Disease) - Pipeline by Apteeus SAS, 2022
- Globoid Cell Leukodystrophy (Krabbe Disease) - Pipeline by Bial - Portela & Ca SA, 2022
- Globoid Cell Leukodystrophy (Krabbe Disease) - Pipeline by BioXcel Corp, 2022
- Globoid Cell Leukodystrophy (Krabbe Disease) - Pipeline by Forge Biologics Inc, 2022
- Globoid Cell Leukodystrophy (Krabbe Disease) - Pipeline by Gain Therapeutics Inc, 2022
- Globoid Cell Leukodystrophy (Krabbe Disease) - Pipeline by M6P Therapeutics, 2022
- Globoid Cell Leukodystrophy (Krabbe Disease) - Pipeline by Neurogene Inc, 2022
- Globoid Cell Leukodystrophy (Krabbe Disease) - Pipeline by Polaryx Therapeutics Inc, 2022
- Globoid Cell Leukodystrophy (Krabbe Disease) - Pipeline by Vascumab LLC, 2022
- Globoid Cell Leukodystrophy (Krabbe Disease) - Dormant Projects, 2022
- Globoid Cell Leukodystrophy (Krabbe Disease) - Discontinued Products, 2022
- Number of Products under Development for Globoid Cell Leukodystrophy (Krabbe Disease), 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Apteeus SAS
- Bial - Portela & Ca SA
- BioXcel Corp
- Forge Biologics Inc
- Gain Therapeutics Inc
- M6P Therapeutics
- Neurogene Inc
- Polaryx Therapeutics Inc
- Vascumab LLC
